Please login to the form below

Not currently logged in
Email:
Password:

Icon appoints Allergan’s Ira Spector

He also has 17 years’ experience at Wyeth
icon ira spector

Dr Ira Spector has left his senior role at Allergan to join the clinical research organisation (CRO) Icon as executive VP, analytics and consulting.

Dr Spector was most recently senior VP of global development operations at Allergan where he spent four years. Prior to this he spent 17 years at Wyeth, leaving shortly after the company's takeover by Pfizer.

In his new role at Icon Dr Spector will lead the company's global consulting and drug development services and will also be responsible for Icon's business process improvement and analytics capabilities.

Icon's chief operating officer Dr Steve Cutler commented on the new appointment: “His extensive experience in managing some of the world's largest trials in areas such as oncology, vaccines and CNS, coupled with his expertise in using technology to drive innovation and process improvement, will enable us to provide further strategic input to our customers' drug and device programmes.”

10th September 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics